Published November, 2014
By Val R Adams
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.

---

Published November, 2014
By Antonio Tito Fojo
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book presents the first comprehensive exploration of the dynamic potential of microtubules anti-cancer targets. Written by leading anti-cancer researchers, this groundbreaking volume collects the most current microtubule research available and investigates the potential of microtubules in cancer therapy.

---

Published January, 2014
By William D. Figg, Cindy H. Chau, Michelle A. Rudek, Howard L. McLeod and William Figg
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book offers a detailed, step-by-step guide to the successful design and approval of anticancer drugs. It covers all steps, from the identification of cancer-specific molecular targets to clinical trial design and all the phases of clinical trials.

---

Published January, 2014
By Steven Kanner
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

In this volume, the major metabolic alterations identified in cancer and tumor-associated cells are explored, including discussions of former and emerging approaches to drug development in targeting cancer cell metabolism.

---

Published November, 2013
By Giovanni Melillo
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The imbalance between rapidly proliferating tumor cells and inadequate and inefficient tumor vasculature leads to a decrease in oxygen levels (hypoxia and/or anoxia) in tumor tissues.

---

Published October, 2013
By Masaki Terabe and Jay A. Berzofsky
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book will cover primary roles of NKT cells in immunity to cancer, in both mouse tumor models and cancer patients. There are several chapters describing general aspects of NKT cells.

---

Published October, 2013
By Yves Pommier
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

DNA topoisomerases represent an essential family of DNA processing enzymes and a large number of topoisomerase inhibitors are used clinically for the treatment of various human cancers.

---

Published October, 2013
By Derek LeRoith
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The book will detail the history, successes, and failures of targeted therapies for cancer, with a particular focus on IGF systems and cancer.

---

Published August, 2013
By Rakesh Kumar
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

At the moment, there is no dedicated book to summarize the roles, the significance, and potential therapeutic targeting of transcriptional factors from the perspective of signaling cascade, and thus, directly impacting the functionality of transcriptional factors in cancer.

---

Published June, 2013
By Beverly A. Teicher
Publisher: Springer (Springer-Verlag New York Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval.

---